US 9878993
DNA-PK inhibitors for treatment of cancer
granted A61KA61K31/506A61K31/53
Quick answer
US patent 9878993 (DNA-PK inhibitors for treatment of cancer) held by Vertex Pharmaceuticals Incorporated expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/506, A61K31/53, A61K31/5377, A61K41/0038